Lung Cancer Stage II Clinical Trials

4 recruiting

Lung Cancer Stage II Trials at a Glance

17 actively recruiting trials for lung cancer stage ii are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 2 with 10 trials, with the heaviest enrollment activity in Winston-Salem, New York, and Guangzhou. Lead sponsors running lung cancer stage ii studies include Sun Yat-sen University, Wake Forest University Health Sciences, and Beth Israel Deaconess Medical Center.

Browse lung cancer stage ii trials by phase

Treatments under study

About Lung Cancer Stage II Clinical Trials

Looking for clinical trials for Lung Cancer Stage II? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Lung Cancer Stage II trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Lung Cancer Stage II clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 117 of 17 trials

Recruiting
Phase 2

Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC

Lung Cancer Stage III
Sun Yat-sen University36 enrolled1 locationNCT03872661
Recruiting
Phase 2

Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

MutationLung Cancer Stage III
Sun Yat-sen University120 enrolled1 locationNCT06563999
Recruiting
Not Applicable

Avecure Flexible Microwave Ablation Probe For Lung Nodules

Lung CancerLung Cancer Stage ILung Cancer Stage II+3 more
Beth Israel Deaconess Medical Center10 enrolled1 locationNCT05281237
Recruiting
Phase 1Phase 2

Alectinib Pharmacokinetic in Patients With NSCLC

ALK Gene MutationNon-small Cell Lung Cancer Stage IIIB
Instituto Nacional de Cancerologia de Mexico45 enrolled1 locationNCT05713006
Recruiting
Phase 2

Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance

Brain MetastasesNonsmall Cell Lung Cancer Stage III
Wake Forest University Health Sciences60 enrolled1 locationNCT05692635
Recruiting
Phase 2

Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer

Nonsmall Cell Lung Cancer Stage IIIUnresectable Non-Small Cell Lung CarcinomaNonsmall Cell Lung Cancer, Stage II
Wake Forest University Health Sciences28 enrolled1 locationNCT05696782
Recruiting
Phase 2

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

Non-small Cell Lung CancerNon-small Cell Lung Cancer Stage INon-small Cell Lung Cancer Stage II
Stanford University80 enrolled1 locationNCT04585477
Recruiting
Phase 2

Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Stage IVNon-small Cell Lung Cancer Stage IIIC
University of California, Davis56 enrolled1 locationNCT07250477
Recruiting
Phase 2

Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery

Lung CancerLung Cancer Stage IILung Cancer Stage III
Memorial Sloan Kettering Cancer Center60 enrolled7 locationsNCT04991025
Recruiting
Phase 1Phase 2

AK129 Combination Therapy for Advanced Solid Tumors

Head and Neck Squamous Cell Carcinoma (HNSCC)Advanced Solid TumorsColorectal Adenocarcinoma+1 more
Akeso230 enrolled1 locationNCT06943820
Recruiting
Phase 3

Bovine Reinforcement in Stomach, Colorectal and Lung Operation

Rectal Cancer Stage IIILung Cancer Stage III
Shanghai Cingularbio Co. Ltd172 enrolled1 locationNCT06968221
Recruiting
Phase 2

Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®

Lung CancerLung Cancer Stage ILung Cancer Stage II
CivaTech Oncology40 enrolled1 locationNCT03290534
Recruiting

Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC

Lung Cancer Stage III
University Medical Center Groningen248 enrolled6 locationsNCT06111807
Recruiting

Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients

Non-small Cell Lung Cancer MetastaticNon-small Cell Lung Cancer Stage IIMetastatic Non-small Cell Lung Cancer (NSCLC)
AIO-Studien-gGmbH12,400 enrolled1 locationNCT02622581
Recruiting

Oral Chemotherapeutic Drugs Were Analyzed in Patients With Driver Gene Negative Locally Advanced/Advanced Non-small Cell Lung Cancer With PS Score 2 A Prospective, Single-arm, Multicenter, Observational Study on the Efficacy and Safety of Radiochemotherapy Combined With PD-1 Inhibitor

Non-small Cell Lung Cancer Stage IIIB/IV
Guangzhou Institute of Respiratory Disease30 enrolled1 locationNCT06310915
Recruiting

COr Loco-regional Advanced Lung Cancer Treated With Chemo-radiotherapy (COLA)

Radiation ToxicityCardiac ToxicityLung Cancer Stage II+2 more
Odense University Hospital100 enrolled1 locationNCT05258448
Recruiting

A Machine Learning Approach to Identify Patients With Resected Non-small-cell Lung Cancer With High Risk of Relapse

Non-small Cell Lung Cancer Stage IIIA
University Hospital, Toulouse60 enrolled1 locationNCT05732974